{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:49:02Z","timestamp":1768510142094,"version":"3.49.0"},"posted":{"date-parts":[[2024,1,18]]},"group-title":"Microbiology","reference-count":69,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,1,18]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  <jats:italic>Yersinia pestis<\/jats:italic>\n                  , one of the deadliest bacterial pathogens ever known, is responsible for three plague pandemics and several epidemics, with over 200 million deaths during recorded history. Due to high genomic plasticity,\n                  <jats:italic>Y. pestis<\/jats:italic>\n                  is amenable to genetic mutations as well as genetic engineering that can lead to the emergence or intentional development of pan-drug resistant strains. The dissemination of such\n                  <jats:italic>Y. pestis<\/jats:italic>\n                  strains could be catastrophic, with public health consequences far more daunting than those caused by the recent COVID-19 pandemic. Thus, there is an urgent need to develop novel, safe, and effective treatment approaches for managing\n                  <jats:italic>Y. pestis<\/jats:italic>\n                  infections. This includes infections by antigenically distinct strains for which vaccines, none FDA approved yet, may not be effective, and those that cannot be controlled by approved antibiotics. Lytic bacteriophages provide one such alternative approach. In this study, we examined post-exposure efficacy of a bacteriophage cocktail, YPP-401, to combat pneumonic plague caused by\n                  <jats:italic>Y. pestis<\/jats:italic>\n                  CO92. YPP-401 is a four-phage preparation with a 100% lytic activity against a panel of 68 genetically diverse\n                  <jats:italic>Y. pestis<\/jats:italic>\n                  strains. Using a pneumonic plague aerosol challenge model in gender-balanced Brown Norway rats, YPP-401 demonstrated \u223c88% protection when delivered 18 hours post-exposure for each of two administration routes (i.e., intraperitoneal and intranasal) in a dose-dependent manner. Our studies suggest that YPP-401 could provide an innovative, safe, and effective approach for managing\n                  <jats:italic>Y. pestis<\/jats:italic>\n                  infections, including those caused by naturally occurring or intentionally developed strains that cannot be managed by vaccines in development and antibiotics.\n                <\/jats:p>","DOI":"10.1101\/2024.01.17.576055","type":"posted-content","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T19:15:11Z","timestamp":1705605311000},"source":"Crossref","is-referenced-by-count":2,"title":["A Bacteriophage Cocktail Targeting\n                  <i>Yersinia pestis<\/i>\n                  Provides Strong Post-Exposure Protection in a Rat Pneumonic Plague Model"],"prefix":"10.64898","author":[{"given":"Paul B.","family":"Kilgore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Sha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily K.","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blake H.","family":"Neil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer E.","family":"Peel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Hittle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joelle","family":"Woolston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Sulakvelidze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok K.","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024012121050436000_2024.01.17.576055v1.1","first-page":"S78","article-title":"Yersinia pestis and the plague","volume":"119","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"2024012121050436000_2024.01.17.576055v1.2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-019-0105-9","article-title":"Plague vaccine: recent progress and prospects","volume":"4","year":"2019","journal-title":"NPJ Vaccines"},{"key":"2024012121050436000_2024.01.17.576055v1.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1966.03100140113030"},{"key":"2024012121050436000_2024.01.17.576055v1.4","doi-asserted-by":"publisher","DOI":"10.3201\/eid0809.010536"},{"key":"2024012121050436000_2024.01.17.576055v1.5","unstructured":"McGovern TW , Friedlander AM . 1997. Plague, p 479\u2013502. In Frederick R , Sidell MD , Ernest T , Takafuji MD (ed), Medical Aspects of Chemical and Biological Warfare. Office of The Surgeon General at TMM Publications, Borden Institute, Walter Reed Army Medical Center, Washington, DC."},{"key":"2024012121050436000_2024.01.17.576055v1.6","unstructured":"Hoffman D . 2010. The Dead Hand: the untold story of the cold war arms race and its dangerous legacy. Anchor."},{"key":"2024012121050436000_2024.01.17.576055v1.7","unstructured":"NIAID. 2018. NIAID Emerging Infectious Diseases\/ Pathogens. https:\/\/www.niaid.nih.gov\/research\/emerging-infectious-diseases-pathogens. Accessed November 4, 2021."},{"key":"2024012121050436000_2024.01.17.576055v1.8","unstructured":"U.S. Centers for Disease CaP. 2018. Bioterrorism Agents\/Diseases. https:\/\/emergency.cdc.gov\/agent\/agentlist-category.asp. Accessed November 4, 2021."},{"key":"2024012121050436000_2024.01.17.576055v1.9","first-page":"e00044","article-title":"Yersinia pestis: the Natural History of Plague","volume":"34","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"2024012121050436000_2024.01.17.576055v1.10","doi-asserted-by":"publisher","DOI":"10.3201\/eid2101.140564"},{"key":"2024012121050436000_2024.01.17.576055v1.11","doi-asserted-by":"crossref","unstructured":"Rosenzweig JA , Hendrix EK , Chopra AK . 2021. Plague vaccines: new developments in an ongoing search, vol 105, p 4931\u20134941. Springer Science and Business Media Deutschland GmbH.","DOI":"10.1007\/s00253-021-11389-6"},{"key":"2024012121050436000_2024.01.17.576055v1.12","unstructured":"WHO. 2023. Global consultation on Plague Vaccines. https:\/\/www.who.int\/news-room\/events\/detail\/2023\/10\/12\/default-calendar\/global-consultation-on-plague-vaccines."},{"key":"2024012121050436000_2024.01.17.576055v1.13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.vaccine.2018.11.022","article-title":"Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine","volume":"37","year":"2019","journal-title":"Vaccine"},{"key":"2024012121050436000_2024.01.17.576055v1.14","doi-asserted-by":"crossref","unstructured":"Williamson ED . 2012. The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague. Adv Prev Med 2012:365980.","DOI":"10.1155\/2012\/365980"},{"key":"2024012121050436000_2024.01.17.576055v1.15","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-148-6-1687"},{"key":"2024012121050436000_2024.01.17.576055v1.16","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-42-4-264"},{"key":"2024012121050436000_2024.01.17.576055v1.17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1128\/br.40.4.793-802.1976","article-title":"Who discovered bacteriophage?","volume":"40","year":"1976","journal-title":"Bacteriological reviews"},{"key":"2024012121050436000_2024.01.17.576055v1.18","unstructured":"Summers WC . 1999. Felix d\u2019Herelle and the origins of molecular biology, p 47\u201359, Bacteriophage discovered. Yale University Press, New Have, CT."},{"key":"2024012121050436000_2024.01.17.576055v1.19","first-page":"1393","article-title":"Essai de tra\u00eetement de la peste bubonique par le bact\u00e9riophage","volume":"33","year":"1925","journal-title":"La Presse M\u00e9d"},{"key":"2024012121050436000_2024.01.17.576055v1.20","doi-asserted-by":"crossref","unstructured":"Sulakvelidze A , Kutter E . 2005. Bacteriophage therapy in humans, p 381\u2013436. In Kutter E , Sulakvelidze A (ed), Bacteriophages: Biology and Application. CRC Press, Boca Raton, FL.","DOI":"10.1201\/9780203491751.ch14"},{"key":"2024012121050436000_2024.01.17.576055v1.21","doi-asserted-by":"crossref","unstructured":"Sulakvelidze A . 2012. Challenges of bacteriophage therapy, p S13.1 - S13.20. In Hodges N , Hanlon G (ed), Industrial Pharmaceutical Microbiology. Euromed Communications, Ltd., Passfield, England.","DOI":"10.1016\/S1525-0016(16)35835-X"},{"key":"2024012121050436000_2024.01.17.576055v1.22","doi-asserted-by":"crossref","unstructured":"Moses S , Vagima Y , Tidhar A , Aftalion M , Mamroud E , Rotem S , Steinberger-Levy I . 2021. Characterization of Yersinia pestis Phage Lytic Activity in Human Whole Blood for the Selection of Efficient Therapeutic Phages. Viruses 13.","DOI":"10.3390\/v13010089"},{"key":"2024012121050436000_2024.01.17.576055v1.23","doi-asserted-by":"publisher","DOI":"10.4161\/bact.22240"},{"key":"2024012121050436000_2024.01.17.576055v1.24","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3390\/v15071484","article-title":"New Bacteriophages with Podoviridal Morphotypes Active against Yersinia pestis: Characterization and Application Potential","volume":"15","year":"2023","journal-title":"Viruses"},{"key":"2024012121050436000_2024.01.17.576055v1.25","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-3561-7_41"},{"key":"2024012121050436000_2024.01.17.576055v1.26","doi-asserted-by":"crossref","unstructured":"Vagima Y , Gur D , Aftalion M , Moses S , Levy Y , Makovitzki A , Holtzman T , Oren Z , Segula Y , Fatelevich E , Tidhar A , Zauberman A , Rotem S , Mamroud E , Steinberger-Levy I . 2022. Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague. Viruses 14.","DOI":"10.1101\/2022.02.07.479346"},{"key":"2024012121050436000_2024.01.17.576055v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2008.11.009"},{"key":"2024012121050436000_2024.01.17.576055v1.28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/v13020296","article-title":"T4-like Bacteriophages Isolated from Pig Stools Infect Yersinia pseudotuberculosis and Yersinia pestis Using LPS and OmpF as Receptors","volume":"13","year":"2021","journal-title":"Viruses"},{"key":"2024012121050436000_2024.01.17.576055v1.29","doi-asserted-by":"publisher","DOI":"10.4161\/bact.1.2.15456"},{"key":"2024012121050436000_2024.01.17.576055v1.30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.675"},{"key":"2024012121050436000_2024.01.17.576055v1.31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00632-11"},{"key":"2024012121050436000_2024.01.17.576055v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2015.11.008"},{"key":"2024012121050436000_2024.01.17.576055v1.33","unstructured":"WHO WHO. 1970. Health aspects of chemical and biological weapons World Health Organization Geneva, Switzerland."},{"key":"2024012121050436000_2024.01.17.576055v1.34","first-page":"794","article-title":"The 1994 plague epidemic of India: molecular diagnosis and characterization of Yersinia pestis isolates from Surat and Beed","volume":"71","year":"1996","journal-title":"Curr Sci"},{"key":"2024012121050436000_2024.01.17.576055v1.35","doi-asserted-by":"publisher","DOI":"10.1089\/vbz.2011.0748"},{"key":"2024012121050436000_2024.01.17.576055v1.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709043371004"},{"key":"2024012121050436000_2024.01.17.576055v1.37","doi-asserted-by":"crossref","first-page":"e0009324","DOI":"10.1371\/journal.pntd.0009324","article-title":"A novel mechanism of streptomycin resistance in Yersinia pestis: Mutation in the rpsL gene","volume":"15","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2024012121050436000_2024.01.17.576055v1.38","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab606"},{"key":"2024012121050436000_2024.01.17.576055v1.39","unstructured":"Anonymous. 2021. Microsoft founder Bill Gates warns of bioterrorist attacks and urges world leaders to use \u2018germ games\u2019 to prepare in interview with Jeremy Hunt, on Sky News. https:\/\/news.sky.com\/story\/microsoft-founder-bill-gates-warns-of-bioterrorist-attacks-and-urges-world-leaders-to-use-germ-games-to-prepare-in-interview-with-jeremy-hunt-12459391. Accessed November 8, 2021."},{"key":"2024012121050436000_2024.01.17.576055v1.40","doi-asserted-by":"publisher","DOI":"10.4161\/bact.1.2.14590"},{"key":"2024012121050436000_2024.01.17.576055v1.41","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.micro.55.1.437"},{"key":"2024012121050436000_2024.01.17.576055v1.42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.6.2170"},{"key":"2024012121050436000_2024.01.17.576055v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(85)80505-9"},{"key":"2024012121050436000_2024.01.17.576055v1.44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1479-5876-12-119","article-title":"Phage idiotype vaccination: first phase I\/II clinical trial in patients with multiple myeloma","volume":"12","year":"2014","journal-title":"J Transl Med"},{"key":"2024012121050436000_2024.01.17.576055v1.45","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.micro.55.1.437"},{"key":"2024012121050436000_2024.01.17.576055v1.46","first-page":"1393","article-title":"Essai de traitement de la peste bubonique par le bacteriophage","volume":"33","year":"1925","journal-title":"Presse Med"},{"key":"2024012121050436000_2024.01.17.576055v1.47","doi-asserted-by":"crossref","first-page":"e25098","DOI":"10.4161\/bact.25098","article-title":"Bacteriophages for managing Shigella in various clinical and non-clinical settings","volume":"3","year":"2013","journal-title":"Bacteriophage"},{"key":"2024012121050436000_2024.01.17.576055v1.48","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.649-659.2001"},{"key":"2024012121050436000_2024.01.17.576055v1.49","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1111"},{"key":"2024012121050436000_2024.01.17.576055v1.50","doi-asserted-by":"publisher","DOI":"10.4161\/bact.20757"},{"key":"2024012121050436000_2024.01.17.576055v1.51","first-page":"135","article-title":"[Use of combined phages in suppurative-inflammatory diseases]","volume":"51","year":"1974","journal-title":"Zhurnal mikrobiologii, epidemiologii, i immunobiologii"},{"key":"2024012121050436000_2024.01.17.576055v1.52","first-page":"693","article-title":"[Successful treatment with bacteriophage in purulent cerebrospinal meningitis in a newborn]","volume":"33","year":"1999","journal-title":"Neurologia i neurochirurgia polska"},{"key":"2024012121050436000_2024.01.17.576055v1.53","unstructured":"Meladze GD , Mebuke MG , Chkhetiia N , Kiknadze N , Koguashvili GG . 1982. [Efficacy of staphylococcal bacteriophage in the treatment of purulent lung and pleural diseases]. Grudnaia khirurgiia:53\u20136."},{"key":"2024012121050436000_2024.01.17.576055v1.54","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00327"},{"key":"2024012121050436000_2024.01.17.576055v1.55","first-page":"1100","article-title":"Formation of therapeutic phage cocktail and endolysin to highly multi-drug resistant Acinetobacter baumannii: in vitro and in vivo study","volume":"21","year":"2018","journal-title":"Iran J Basic Med Sci"},{"key":"2024012121050436000_2024.01.17.576055v1.56","doi-asserted-by":"crossref","first-page":"197734","DOI":"10.1016\/j.virusres.2019.197734","article-title":"Efficacy of a phage cocktail in controlling phage resistance development in multidrug resistant Acinetobacter baumannii","volume":"272","year":"2019","journal-title":"Virus Res"},{"key":"2024012121050436000_2024.01.17.576055v1.57","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.9.2.94"},{"key":"2024012121050436000_2024.01.17.576055v1.58","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00597-12"},{"key":"2024012121050436000_2024.01.17.576055v1.59","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01067-12"},{"key":"2024012121050436000_2024.01.17.576055v1.60","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.02778-14"},{"key":"2024012121050436000_2024.01.17.576055v1.61","first-page":"220058","article-title":"Means to facilitate the overcoming of gastric juice barrier by a therapeutic staphylococcal bacteriophage A5\/80","volume":"8","year":"2017","journal-title":"Frontiers in Microbiology"},{"key":"2024012121050436000_2024.01.17.576055v1.62","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3390\/biom11050724","article-title":"Antibiotic Therapy of Plague: A Review","volume":"11","year":"2021","journal-title":"Biomolecules"},{"key":"2024012121050436000_2024.01.17.576055v1.63","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.10.1.35"},{"key":"2024012121050436000_2024.01.17.576055v1.64","doi-asserted-by":"crossref","unstructured":"Li J , Jia H , Cai X , Zhong H , Feng Q , Sunagawa S . 2014. An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol 32.","DOI":"10.1038\/nbt.2942"},{"key":"2024012121050436000_2024.01.17.576055v1.65","doi-asserted-by":"crossref","unstructured":"Qin J , Li R , Raes J , Arumugam M , Burgdorf KS , Manichanh C . 2010. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464.","DOI":"10.1038\/nature08821"},{"key":"2024012121050436000_2024.01.17.576055v1.66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13073-016-0307-y","article-title":"The healthy human microbiome","volume":"8","year":"2016","journal-title":"Genome Medicine"},{"key":"2024012121050436000_2024.01.17.576055v1.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2010.10.002"},{"key":"2024012121050436000_2024.01.17.576055v1.68","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01529-07"},{"key":"2024012121050436000_2024.01.17.576055v1.69","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.2008\/017335-0"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.01.17.576055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:48:34Z","timestamp":1768456114000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.01.17.576055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":69,"URL":"https:\/\/doi.org\/10.1101\/2024.01.17.576055","relation":{},"subject":[],"published":{"date-parts":[[2024,1,18]]},"subtype":"preprint"}}